MTOR and pancreatic neoplasm: We also failed to show significant anti-angiogenic effects in the orthotopic primary pancreatic cancer xenografts, which is in contrast with other groups who have reported pronounced anti-angiogenic effects by mTor inhibitors used to treat xenografts established from pancreatic cancer cell lines (Azzariti et al, 2008; Manegold et al, 2008).